#BEGIN_DRUGCARD DB03674

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
49747

# Chemical_Formula:
CH3Hg

# Chemical_IUPAC_Name:
methylmercuryylium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Methyl Mercury Ion

# HET_ID:
HGC

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/CH3.Hg/h1H3;/q;+1

# InChI_Key:
InChIKey=DBUXSCUEGJMZAE-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3674

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
215.62

# Molecular_Weight_Mono:
216.9941007

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1FO8

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.06

# Predicted_LogS:
-0.52

# Predicted_Water_Solubility:
7.63e+01 g/l

# Primary_Accession_No:
DB03674

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
6860

# PubChem_Substance_ID:
46504959

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01739

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[Hg+]

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:30 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CA2

# Drug_Target_1_GenBank_ID_Gene:
M77181

# Drug_Target_1_GenBank_ID_Protein:
179780

# Drug_Target_1_GeneCard_ID:
CA2

# Drug_Target_1_Gene_Name:
CA2

# Drug_Target_1_Gene_Sequence:
>783 bp
ATGTCCCATCACTGGGGGTACGGCAAACACAACGGACCTGAGCACTGGCATAAGGACTTC
CCCATTGCCAAGGGAGAGCGCCAGTCCCCTGTTGACATCGACACTCATACAGCCAAGTAT
GACCCTTCCCTGAAGCCCCTGTCTGTTTCCTATGATCAAGCAACTTCCCTGAGGATCCTC
AACAATGGTCATGCTTTCAACGTGGAGTTTGATGACTCTCAGGACAAAGCAGTGCTCAAG
GGAGGACCCCTGGATGGCACTTACAGATTGATTCAGTTTCACTTTCACTGGGGTTCACTT
GATGGACAAGGTTCAGAGCATACTGTGGATAAAAAGAAATATGCTGCAGAACTTCACTTG
GTTCACTGGAACACCAAATATGGGGATTTTGGGAAAGCTGTGCAGCAACCTGATGGACTG
GCCGTTCTAGGTATTTTTTTGAAGGTTGGCAGCGCTAAACCGGGCCTTCAGAAAGTTGTT
GATGTGCTGGATTCCATTAAAACAAAGGGCAAGAGTGCTGACTTCACTAACTTCGATCCT
CGTGGCCTCCTTCCTGAATCCTTGGATTACTGGACCTACCCAGGCTCACTGACCACCCCT
CCTCTTCTGGAATGTGTGACCTGGATTGTGCTCAAGGAACCCATCAGCGTCAGCAGCGAG
CAGGTGTTGAAATTCCGTAAACTTAACTTCAATGGGGAGGGTGAACCCGAAGAACTGATG
GTGGACAACTGGCGCCCAGCTCAGCCACTGAAGAACAGGCAAATCAAAGCTTCCTTCAAA
TAA

# Drug_Target_1_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_1_General_References:
11076507	Cox JD, Hunt JA, Compher KM, Fierke CA, Christianson DW: Structural influence of hydrophobic core residues on metal binding and specificity in carbonic anhydrase II. Biochemistry. 2000 Nov 14;39(45):13687-94.
1542674	Roth DE, Venta PJ, Tashian RE, Sly WS: Molecular basis of human carbonic anhydrase II deficiency. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1804-8.
1928091	Venta PJ, Welty RJ, Johnson TM, Sly WS, Tashian RE: Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (107 His----Tyr): complete structure of the normal human CA II gene. Am J Hum Genet. 1991 Nov;49(5):1082-90.
3000449	Venta PJ, Montgomery JC, Hewett-Emmett D, Tashian RE: Comparison of the 5' regions of human and mouse carbonic anhydrase II genes and identification of possible regulatory elements. Biochim Biophys Acta. 1985 Dec 18;826(4):195-201.
3108857	Montgomery JC, Venta PJ, Tashian RE, Hewett-Emmett D: Nucleotide sequence of human liver carbonic anhydrase II cDNA. Nucleic Acids Res. 1987 Jun 11;15(11):4687.
3121496	Murakami H, Marelich GP, Grubb JH, Kyle JW, Sly WS: Cloning, expression, and sequence homologies of cDNA for human carbonic anhydrase II. Genomics. 1987 Oct;1(2):159-66.
3151019	Eriksson AE, Jones TA, Liljas A: Refined structure of human carbonic anhydrase II at 2.0 A resolution. Proteins. 1988;4(4):274-82.
3151020	Eriksson AE, Kylsten PM, Jones TA, Liljas A: Crystallographic studies of inhibitor binding sites in human carbonic anhydrase II: a pentacoordinated binding of the SCN- ion to the zinc at high pH. Proteins. 1988;4(4):283-93.
4207120	Lin KT, Deutsch HF: Human carbonic anhydrases. XII. The complete primary structure of the C isozyme. J Biol Chem. 1974 Apr 25;249(8):2329-37.
4621826	Liljas A, Kannan KK, Bergsten PC, Waara I, Fridborg K, Strandberg B, Carlbom U, Jarup L, Lovgren S, Petef M: Crystal structure of human carbonic anhydrase C. Nat New Biol. 1972 Feb 2;235(57):131-7.
6407977	Jones GL, Shaw DC: A chemical and enzymological comparison of the common major human erythrocyte carbonic anhydrase II, its minor component, and a new genetic variant, CA II Melbourne (237 Pro leads to His). Hum Genet. 1983;63(4):392-9.
6817747	Jones GL, Sofro AS, Shaw DC: Chemical and enzymological characterization of an Indonesian variant of human erythrocyte carbonic anhydrase II, CAII Jogjakarta (17 Lys leads to Glu). Biochem Genet. 1982 Oct;20(9-10):979-1000.
823150	Henderson LE, Henriksson D, Nyman PO: Primary structure of human carbonic anhydrase C. J Biol Chem. 1976 Sep 25;251(18):5457-63.
8834238	Soda H, Yukizane S, Yoshida I, Koga Y, Aramaki S, Kato H: A point mutation in exon 3 (His 107-->Tyr) in two unrelated Japanese patients with carbonic anhydrase II deficiency with central nervous system involvement. Hum Genet. 1996 Apr;97(4):435-7.
9143915	Hu PY, Lim EJ, Ciccolella J, Strisciuglio P, Sly WS: Seven novel mutations in carbonic anhydrase II deficiency syndrome identified by SSCP and direct sequencing analysis. Hum Mutat. 1997;9(5):383-7.
9541386	Stams T, Chen Y, Boriack-Sjodin PA, Hurt JD, Liao J, May JA, Dean T, Laipis P, Silverman DN, Christianson DW: Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Protein Sci. 1998 Mar;7(3):556-63.

# Drug_Target_1_HGNC_ID:
HGNC:1373

# Drug_Target_1_HPRD_ID:
02023

# Drug_Target_1_ID:
357

# Drug_Target_1_Locus:
8q22

# Drug_Target_1_Molecular_Weight:
29115

# Drug_Target_1_Name:
Carbonic anhydrase 2

# Drug_Target_1_Number_of_Residues:
259

# Drug_Target_1_PDB_ID:
1T9N

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00194	Carb_anhydrase

# Drug_Target_1_Protein_Sequence:
>Carbonic anhydrase 2
SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILN
NGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLV
HWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPR
GLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMV
DNWRPAQPLKNRQIKASFK

# Drug_Target_1_Reaction:
H2CO3 = CO2 + H2O

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Reversible hydration of carbon dioxide

# Drug_Target_1_SwissProt_ID:
P00918

# Drug_Target_1_SwissProt_Name:
CAH2_HUMAN

# Drug_Target_1_Synonyms:
CA-II
Carbonate dehydratase II
Carbonic anhydrase C
Carbonic anhydrase II
EC 4.2.1.1

# Drug_Target_1_Theoretical_pI:
7.47

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
MGAT1

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
7029

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P26572

# Drug_Target_2_SwissProt_Name:
MGAT1_HUMAN

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
L42023

# Drug_Target_3_GenBank_ID_Protein:
1574067

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
HI_1034

# Drug_Target_3_Gene_Sequence:
>492 bp
ATGCCATCTTTTGATATTGTTTCTGAAATTACTTTACACGAAGTCCGTAATGCAGTGGAA
AATGCCAACCGTGTGCTTAGCACGCGTTATGATTTTCGTGGTGTCGAAGCGGTAATTGAA
TTAAATGAAAAAAATGAAACGATTAAAATTACTACAGAATCTGATTTCCAACTTGAACAA
TTAATTGAGATTTTAATTGGATCTTGCATTAAACGTGGTATTGAGCACAGTTCTTTAGAT
ATTCCAGCAGAAAGCGAACACCACGGTAAACTTTACAGTAAAGAAATCAAACTTAAACAG
GGTATTGAAACAGAGATGGCGAAGAAAATTACTAAATTAGTAAAAGATTCTAAAATCAAA
GTTCAAACTCAAATTCAGGGCGAACAAGTGCGTGTGACAGGTAAGTCACGCGATGATTTA
CAGGCAGTCATTCAACTTGTTAAAAGTGCTGAATTAGGCCAACCATTCCAATTTAATAAT
TTTAGAGATTAG

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
10675023	Langen H, Takacs B, Evers S, Berndt P, Lahm HW, Wipf B, Gray C, Fountoulakis M: Two-dimensional map of the proteome of Haemophilus influenzae. Electrophoresis. 2000 Jan;21(2):411-29.
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
3226

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
18551

# Drug_Target_3_Name:
UPF0234 protein HI1034

# Drug_Target_3_Number_of_Residues:
163

# Drug_Target_3_PDB_ID:
1IN0

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF04461	DUF520

# Drug_Target_3_Protein_Sequence:
>UPF0234 protein HI1034
MPSFDIVSEITLHEVRNAVENANRVLSTRYDFRGVEAVIELNEKNETIKITTESDFQLEQ
LIEILIGSCIKRGIEHSSLDIPAESEHHGKLYSKEIKLKQGIETEMAKKITKLVKDSKIK
VQTQIQGEQVRVTGKSRDDLQAVIQLVKSAELGQPFQFNNFRD

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
P44096

# Drug_Target_3_SwissProt_Name:
Y1034_HAEIN

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
6.13

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Centrosome

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
CDC25B

# Drug_Target_4_GenBank_ID_Gene:
M81934

# Drug_Target_4_GenBank_ID_Protein:
180173

# Drug_Target_4_GeneCard_ID:
CDC25B

# Drug_Target_4_Gene_Name:
CDC25B

# Drug_Target_4_Gene_Sequence:
>1701 bp
ATGGAGGTGCCCCAGCCGGAGCCCGCGCCAGGCTCGGCTCTCAGTCCAGCAGGCGTGTGC
GGTGGCGCCCAGCGTCCGGGCCACCTCCCGGGCCTCCTGCTGGGATCTCATGGCCTCCTG
GGGTCCCCGGTGCGGGCGGCCGCTTCCTCGCCGGTCACCACCCTCACCCAGACCATGCAC
GACCTCGCCGGGCTCGGCAGCCGCAGCCGCCTGACGCACCTATCCCTGTCTCGACGGGCA
TCCGAATCCTCCCTGTCGTCTGAATCCTCCGAATCTTCTGATGCAGGTCTCTGCATGGAT
TCCCCCAGCCCTATGGACCCCCACATGGCGGAGCAGACGTTTGAACAGGCCATCCAGGCA
GCCAGCCGGATCATTCGAAACGAGCAGTTTGCCATCAGACGCTTCCAGTCTATGCCGGTG
AGGCTGCTGGGCCACAGCCCCGTGCTTCGGAACATCACCAACTCCCAGGCGCCCGACGGC
CGGAGGAAGAGCGAGGCGGGCAGTGGAGCTGCCAGCAGCTCTGGGGAAGACAAGGAGAAT
GATGGATTTGTCTTCAAGATGCCATGGAAGCCCACACATCCCAGCTCCACCCATGCTCTG
GCAGAGTGGGCCAGCCGCAGGGAAGCCTTTGCCCAGAGACCCAGCTCGGCCCCCGACCTG
ATGTGTCTCAGTCCTGACCGGAAGATGGAAGTGGAGGAGCTCAGCCCCCTGGCCCTAGGT
CGCTTCTCTCTGACCCCTGCAGAGGGGGATACTGAGGAAGATGATGGATTTGTGGACATC
CTAGAGAGTGACTTAAAGGATGATGATGCAGTTCCCCCAGGCATGGAGAGTCTCATTAGT
GCCCCACTGGTCAAGACCTTGGAAAAGGAAGAGGAAAAGGACCTCGTCATGTACAGCAAG
TGCCAGCGGCTCTTCCGCTCTCCGTCCATGCCCTGCAGCGTGATCCGGCCCATCCTCAAG
AGGCTGGAGCGGCCCCAGGACAGGGACACGCCCGTGCAGAATAAGCGGAGGCGGAGCGTG
ACCCCTCCTGAGGAGCAGCAGGAGGCTGAGGAACCTAAAGCCCGCGTCCTCCGCTCAAAA
TCACTGTGTCACGATGAGATCGAGAACCTCCTGGACAGTGACCACCGAGAGCTGATTGGA
GATTACTCTAAGGCCTTCCTCCTACAGACAGTAGACGGAAAGCACCAAGACCTCAAGTAC
ATCTCACCAGAAACGATGGTGGCCCTATTGACGGGCAAGTTCAGCAACATCGTGGATAAG
TTTGTGATTGTAGACTGCAGATACCCCTATGAATATGAAGGCGGGCACATCAAGACTGCG
GTGAACTTGCCCCTGGAACGCGACGCCGAGAGCTTCCTACTGAAGAGCCCCATCGCGCCC
TGTAGCCTGGACAAGAGAGTCATCCTCATTTTCCACTGTGAATTCTCATCTGAGCGTGGG
CCCCGCATGTGCCGTTTCATCAGGGAACGAGACCGTGCTGTCAACGACTACCCCAGCCTC
TACTACCCTGAGATGTATATCCTGAAAGGCGGCTACAAGGAGTTCTTCCCTCAGCACCCG
AACTTCTGTGAACCCCAGGACTACCGGCCCATGAACCACGAGGCCTTCAAGGATGAGCTA
AAGACCTTCCGCCTCAAGACTCGCAGCTGGGCTGGGGAGCGGAGCCGGCGGGAGCTCTGT
AGCCGGCTGCAGGACCAGTGA

# Drug_Target_4_General_Function:
Involved in protein tyrosine phosphatase activity

# Drug_Target_4_General_References:
10543950	Reynolds RA, Yem AW, Wolfe CL, Deibel MR Jr, Chidester CG, Watenpaugh KD: Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. J Mol Biol. 1999 Oct 29;293(3):559-68.
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
1662986	Nagata A, Igarashi M, Jinno S, Suto K, Okayama H: An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells. New Biol. 1991 Oct;3(10):959-68.
1836978	Galaktionov K, Beach D: Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell. 1991 Dec 20;67(6):1181-94.
9188863	Baldin V, Cans C, Superti-Furga G, Ducommun B: Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control? Oncogene. 1997 May 22;14(20):2485-95.

# Drug_Target_4_HGNC_ID:
HGNC:1726

# Drug_Target_4_HPRD_ID:
00307

# Drug_Target_4_ID:
3105

# Drug_Target_4_Locus:
20p13

# Drug_Target_4_Molecular_Weight:
64988

# Drug_Target_4_Name:
M-phase inducer phosphatase 2

# Drug_Target_4_Number_of_Residues:
580

# Drug_Target_4_PDB_ID:
1CWR

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00581	Rhodanese
PF06617	M-inducer_phosp

# Drug_Target_4_Protein_Sequence:
>M-phase inducer phosphatase 2
MEVPQPEPAPGSALSPAGVCGGAQRPGHLPGLLLGSHGLLGSPVRAAASSPVTTLTQTMH
DLAGLGSETPKSQVGTLLFRSRSRLTHLSLSRRASESSLSSESSESSDAGLCMDSPSPMD
PHMAEQTFEQAIQAASRIIRNEQFAIRRFQSMPVRLLGHSPVLRNITNSQAPDGRRKSEA
GSGAASSSGEDKENDGFVFKMPWKPTHPSSTHALAEWASRREAFAQRPSSAPDLMCLSPD
RKMEVEELSPLALGRFSLTPAEGDTEEDDGFVDILESDLKDDDAVPPGMESLISAPLVKT
LEKEEEKDLVMYSKCQRLFRSPSMPCSVIRPILKRLERPQDRDTPVQNKRRRSVTPPEEQ
QEAEEPKARVLRSKSLCHDEIENLLDSDHRELIGDYSKAFLLQTVDGKHQDLKYISPETM
VALLTGKFSNIVDKFVIVDCRYPYEYEGGHIKTAVNLPLERDAESFLLKSPIAPCSLDKR
VILIFHCEFSSERGPRMCRFIRERDRAVNDYPSLYYPEMYILKGGYKEFFPQHPNFCEPQ
DYRPMNHEAFKDELKTFRLKTRSWAGERSRRELCSRLQDQ

# Drug_Target_4_Reaction:
protein tyrosine phosphate + H2O = protein tyrosine + phosphate

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. Directly dephosphorylates CDC2 and stimulates its kinase activity. The three isoforms seem to have a different level of activity

# Drug_Target_4_SwissProt_ID:
P30305

# Drug_Target_4_SwissProt_Name:
MPIP2_HUMAN

# Drug_Target_4_Synonyms:
Dual specificity phosphatase Cdc25B
EC 3.1.3.48

# Drug_Target_4_Theoretical_pI:
6.36

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB03674
